Basilea Pharmaceutica is continuing its quest to develop much-needed new antifungal drugs by penning a deal with Prokaryotics worth at least $48 million.
Basilea Pharmaceutica is continuing its quest to develop much-needed new antifungal drugs by penning a deal with Prokaryotics worth at least $48 million.
No Comments
Leave a comment Cancel